



Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022

September 29, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 29, 2022-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2022, which will take place November 10 – 14, 2022 in Philadelphia, PA. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation that are not available in the abstract.

Poster Presentation Details:

Abstract Title: Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis

Session: SLE – Treatment Poster II

Date/Time: November 13, 2022 from 9:00 AM - 10:30 AM ET

Presenter: Amit Saxena, MD, Assistant Professor, NYU School of Medicine

Abstract Title: Poor Health-Related Quality of Life in Patients with Lupus Nephritis

Session: Patient Outcomes, Preferences, and Attitudes Poster II

Date/Time: November 13, 2022 from 1:00 PM - 3:00 PM ET

Presenter: Cristina Arriens, MD, Clinical Associate Member, Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation

Abstract Title: Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus

Session: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Date/Time: November 12, 2022 from 1:00 PM - 3:00 PM ET

Presenter: Kenneth Kalunian, MD, Professor of Medicine, University of California San Diego

The accepted ACR abstracts are currently available on the congress platform [here](#). Following the conference, the presentation materials will be available in the "Scientific Publications" section of Kezar Life Science's website at www.kezarlifesciences.com.

About Zetomipzomib (KZR-616)

Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1 clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company's platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220929005862/en/): <https://www.businesswire.com/news/home/20220929005862/en/>

Investor Contact:

Gitanjali Jain

Vice President, Investor Relations and External Affairs

gjain@kezarbio.com

Media Contact:

Julia Deutsch

Solebury Strategic Communications

jdeutsch@soleburystrat.com

Source: Kezar Life Sciences, Inc.